Clinical applications of angiotensin-converting enzyme inhibitors.
Although only recently introduced, angiotensin-converting enzyme inhibitors have been utilized to treat a wide variety of clinical disorders. Their uses to date, approved by the Food and Drug Administration, have been in the treatment of refractory hypertension and congestive heart failure. However, they have been evaluated with mixed results in numerous other conditions in which the renin-angiotensin-aldosterone system may play a role. Their current status in the treatment of hypertension, congestive heart failure, and these other conditions is reviewed.
D000806:Angiotensin-Converting Enzyme Inhibitors; D001201:Ascites / Q000188:drug therapy; D001477:Bartter Syndrome / Q000188:drug therapy; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004487:Edema / Q000188:drug therapy; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000188:drug therapy; D011392:Proline / Q000031:analogs & derivatives*; D012084:Renin-Angiotensin System / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D011392:Proline; D002216:Captopril